Lorpucitinib

Modify Date: 2024-01-09 17:25:09

Use of Lorpucitinib

Lorpucitinib is a Gut-Restricted JAK Inhibitor for the research of Inflammatory Bowel Disease[1].

Name	2-{1-[trans-4-(Cyanomethyl)cyclohexyl]-1,5-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2-yl}-N-(2-hydroxy-2-methylpropyl)acetamide
Synonym	More Synonyms

Description	Lorpucitinib is a Gut-Restricted JAK Inhibitor for the research of Inflammatory Bowel Disease[1].
Related Catalog	Signaling Pathways >> JAK/STAT Signaling >> JAK Signaling Pathways >> Epigenetics >> JAK Signaling Pathways >> Stem Cell/Wnt >> JAK Research Areas >> Inflammation/Immunology
References	[1]. Leonard KA, Madge LA, Krawczuk PJ, Wang A, Kreutter KD, Bacani GM, Chai W, Smith RC, Tichenor MS, Harris MC, Malaviya R, Seierstad M, Johnson ME, Venable JD, Kim S, Hirst GC, Mathur AS, Rao TS, Edwards JP, Rizzolio MC, Koudriakova T. Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease. J Med Chem. 2020 Mar 26;63(6):2915-2929.

Imidazo[4,5-d]pyrrolo[2,3-b]pyridine-2-acetamide, 1-[trans-4-(cyanomethyl)cyclohexyl]-1,5-dihydro-N-(2-hydroxy-2-methylpropyl)-

2-{1-[trans-4-(Cyanomethyl)cyclohexyl]-1,5-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2-yl}-N-(2-hydroxy-2-methylpropyl)acetamide